Want to see HK:6609 full AI Analyst Report?
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$35.00 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)32.03K
Market Cap
HK$2.08B
Enterprise ValueHK$664.27
Total Cash (Recent Filing)HK$789.70M
Total Debt (Recent Filing)HK$41.22M
Price to Earnings (P/E)18.4
Beta1.44
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.48
Shares Outstanding31,565,804
10 Day Avg. Volume36,902
30 Day Avg. Volume32,029
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.91
Revenue Forecast (FY)HK$546.64M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingRevenue expansion from roughly HK$15m in 2020 to HK$398m in 2025 indicates substantial business scaling and improving market reach. If maintained, this larger operating base can support stronger fixed-cost absorption, broader commercial investment, and more durable earnings potential.
Improved ProfitabilityThe 2025 return to positive operating and net income, alongside a high gross margin, shows meaningful operating leverage as revenue has expanded. Stronger profitability can improve internal funding capacity and provide a foundation for sustained reinvestment if performance remains consistent.
Conservative Balance SheetVery low leverage gives the company greater financial flexibility than a heavily indebted business and limits the burden of interest and refinancing obligations. The sizable equity base also provides support for continued investment and resilience while the recent turnaround develops.
Bears Say
Profitability Durability UnprovenAlthough 2025 profitability was strong, the immediately preceding loss-making year shows that the improved earnings level has not yet been demonstrated across a sustained period. This creates uncertainty around margin durability and the reliability of future earnings generation.
Volatile Cash GenerationThe shift to approximately HK$154m of operating cash flow and HK$140m of free cash flow is encouraging, but earlier negative results reveal a volatile cash profile. Until positive conversion persists across periods, funding for growth and resilience may remain uneven.
History Of Sizeable LossesPrior sizeable losses have reduced the confidence that current returns represent a stable earnings base rather than an early-stage recovery. Future reinvestment needs could also pressure returns, making sustained profitability important for rebuilding long-term financial quality.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$35.00 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$2.08B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 192 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Aug 31, 2026. The company reported HK$1.874 earnings per share for the quarter.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$1.874 in its last earnings report. Following the earnings report the stock price went up 2.653%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices for ischemic stroke thrombectomy, intracranial stenosis intervention, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access. These medical technologies are utilized for both the prevention and treatment of ischemic stroke, including acute ischemic events and intracranial narrowing, as well as for addressing hemorrhagic stroke. Established in 2016 and previously operating as Shanghai Care Medical Technology Corporation Limited, the company maintains its headquarters in Shanghai, People's Republic of China.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
Venus Medtech (Hangzhou), Inc. Class H
―